Wiesbaden, October 7, 2017 – On the occasion of the 12th German Allergy Congress in Wiesbaden, Germany, from October 5th to 7th , 2017, the Internet platform of myAllergy (www.allergy.de) has been awarded with the Digital Health Heroes Award 2017. Every third German is confronted with an issue of allergy in the course of his or her life. According to current scientific predictions, the trend continues to rise. “On the one hand the research and development of new, safe allergy treatments has made great strides forward in the past few decades. On the other hand, those affected often have inadequate knowledge of allergic diseases and the correct methods of treatment options” reports Prof. Dr. Ludger Klimek, Congress President and President of the Medical Association of German Allergists AeDA. The information platform myAllergy can solve this problem and contribute to lead affected people to qualified therapy by physicians specialized in allergies in an earlier stage.
Digital Health Heroes Award 2017
myAllergy was awarded with the Digital Health Heroes Award 2017 in the category ‘General Allergies’. “The award was granted to an outstanding, medically correct, digital and helpful communication platform about allergies and intolerances”, said Mrs. Sylvia Becker, Managing Director of the ECARF Institute, Berlin. The aim of myAllergy is to increase awareness of the widespread disease of allergy and intolerance among the population and to make the relevance of quality of life of those affected clear. The digital clarification should reduce the ignorance of allergies and point out potential complications such as asthma.
myAllergy in social media
myAllergy mainly focuses on the people suffering from allergies and their specific questions and needs: “What do allergies in children and adolescents mean? How can I recognize an allergy and where can I turn to?” To these and many other questions, myAllergy offers answers and explains complicated medical issues in an understandable way. A Scientific Advisory Board, composed of renowned experts, ensures the substantial quality of the internet platform. myAllergy wants to reach patients and relatives where they daily receive information: for example in the social networks. With a Facebook page myAllergy offers a dialogue and discussion platform in the world’s largest social network.
About HAL Allergy
HAL Allergy Group is active in the field of biopharmaceuticals and is located at the Bio Science Park in Leiden, The Netherlands. Our core business is the development and manufacturing of therapies and diagnostics for allergic diseases. In addition, we offer contract manufacturing services focusing on the production of biopharmaceutical products for (pre-) clinical studies. With offices in major European countries, HAL Allergy is one of the European top players in the allergy immunotherapy business. Established in 1959 HAL Allergy has long experience in developing, producing and selling allergy therapies with an immuno-modulatory effect causing a reduction in symptoms and long-term disease suppression. The allergy therapies are used against common allergies such as hay fever, house dust mites allergy and allergic reactions towards wasp or bee stings. More information is available on: https://www.hal-allergy.com.
The main shareholder of HAL Allergy GmbH is Droege International Group AG, which is an independent Advisory and Investment Company, based in Düsseldorf, Germany. More information is available on: http://www.droege-group.com.
HAL Allergy Group
Manager Corporate Communications
Tel. + 31 (0)88 1959010